https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-07-31 / J Clin Oncol 32, 2014 (suppl 4; abstr 490)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-07-31 / J Clin Oncol 32, 2014 (suppl 4; abstr 490)2014-07-31 11:52:432021-08-09 07:54:15A phase I, open label, dose escalation and cohort expansion study to evaluate the safety and immune response to autologous dendritic cells (DC) transduced with AdGMCA9 (DC-AdGMCAIX) in patients with mRCC.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-07-22 / J Transl Med 2014 Jul;12:209
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-07-22 / J Transl Med 2014 Jul;12:2092014-07-22 00:00:002019-02-15 08:48:43Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised „proof-of-principle“ phase II study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-07-17 / Am. J. Ophthalmol. 2014 Nov;158(5):939-47
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-07-17 / Am. J. Ophthalmol. 2014 Nov;158(5):939-472014-07-17 00:00:002019-02-15 08:49:40Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-07-01 / Immunology 2014 Jul;142(3):396-405
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-07-01 / Immunology 2014 Jul;142(3):396-4052014-07-01 00:00:002019-02-15 08:49:49Melanoma cell lysate induces CCR7 expression and in vivo migration to draining lymph nodes of therapeutic human dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-07-01 / Yonsei Med. J. 2014 Jul;55(4):1014-27
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-07-01 / Yonsei Med. J. 2014 Jul;55(4):1014-272014-07-01 00:00:002019-02-15 08:52:43Identification of pancreatic cancer-associated tumor antigen from HSP-enriched tumor lysate-pulsed human dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-30 / Cell. Mol. Immunol. 2015 Jan;12(1):87-95
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-30 / Cell. Mol. Immunol. 2015 Jan;12(1):87-952014-06-30 00:00:002019-02-15 08:52:07Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-09 / Int. Rev. Immunol. 2014 Oct;33(5):428-40
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-09 / Int. Rev. Immunol. 2014 Oct;33(5):428-402014-06-09 00:00:002019-02-15 08:52:08Ovarian cancer biology and immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3069)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3069)2014-06-01 12:06:002019-07-17 12:06:29Regulatory T-cell inhibition plus antitumor immunotherapy targeted against cytomegalovirus (CMV) in patients with newly diagnosed glioblastoma multiforme (GBM).
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 2005)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 2005)2014-06-01 11:49:162019-07-17 11:49:36A randomized, double-blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr TPS3134)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr TPS3134)2014-06-01 00:00:002014-06-01 00:00:00Autologous dendritic cell vaccination (DCVAC/OvCa) added to standard of care therapy in three open-label randomized phase 2 studies in women with advanced stage ovarian cancer (OC).
